SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 1, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-1822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices)
( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On February 1, 1996, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that its subsidiary, IDT, Inc.
in conjunction with Hemocleanse, Inc. of West
Lafayette, Indiana, has been granted Food and Drug
Administration (FDA) approval to conduct expanded
studies of whole-body extracorporeal hyperthermia (WBH)
procedure utilizing the BioLogic-HT System for
treatment of HIV/AIDS. Dates and hospital location(s)
have not yet been finalized.
BICO further announced that a patent on the WBH
procedure utilizing the BioLogic-HT System,
manufactured by HemoCleanse, was recently granted to
IDT by the US Patent and Trademark Office. As the
Company is positioning itself to market this equipment
and procedure in Europe, patents have also been applied
there and are currently pending.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 1, 1996
